Vland Biotech announced that, following review by the Ministry of Agriculture and Rural Affairs, the "Streptococcus suis, Glaesserella parasuis, and Porcine Circovirus Type 2 Triple Inactivated Vaccine," jointly filed by its wholly owned subsidiary Qingdao Vland Animal Health Group and other entities, has been approved as a Class III new veterinary drug. The "Qingying Granules," jointly filed by the company and other entities, has been approved as a Class IV new veterinary drug. The monitoring period for both is three years. The announcement shows that this triple inactivated vaccine is China's first triple inactivated vaccine for pigs that simultaneously prevents Streptococcus suis disease, Glaesserella parasuis disease, and Porcine Circovirus Type 2 infection. It is used to prevent related diseases, with an immunization period of four months. The prescription of Qingying Granules originates from the classic formula "Qingying Decoction" in the Detailed Analysis of Warm Diseases. Its functions are to clear the nutritive level and resolve toxins, vent heat and nourish yin. It mainly treats the nutritive-level syndrome caused by warm-heat pathogens in pigs.
Qingdao Vland Biotech Co LtdVland Biotech received approval for China's first triple inactivated swine vaccine and Qingying Granules as new veterinary drugs.
Wholly owned subsidiary Qingdao Vland Animal Health Group co-filed and obtained approval for the triple inactivated vaccine.
